euro adhoc: Sartorius AG / Earnings substantially improved over last year’s / Group sales revenue above the previous year’s / Double-digit growth in order intake / Targets for 2004 unchanged / Long-term financing package agreed (E)

Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.

First-half sales revenue of the Sartorius Group rose 2.5% (currency-adjusted: 5.2%) to EUR222.3 million from EUR217.0 million a year ago. We increased sales revenue for the Biotechnology Division 1.6% (currency-adjusted: 4.6%) to EUR111.7 million from EUR109.9 million. For the Mechatronics Division, sales revenue grew 3.3% (currency-adjusted: 5.9%) to EUR110.6 million from EUR107.1 million a year earlier.

We raised order intake 10.4% (currency adjusted: 13.9%) to EUR242.3 million from EUR219.4 million a year ago. For the Biotechnology Division, order intake jumped 12.0%; for the Mechatronics Division, it climbed 8.7%.

The positive earnings trend of the first quarter continued on into the second quarter of 2004. We boosted first-half EBITDA to EUR22.5 million (previous year: EUR9.1 million) and EBIT to EUR11.6 million (previous year: - EUR2.1 million). For the Biotechnology Division, we improved EBIT to EUR5.7 million (previous year incl. Environmental Technology: EUR0.8 million) and for the Mechatronics Division, we increased it to EUR5.9 million (previous year: - EUR2.9 million).

Net cash flow rose to EUR13.2 million from EUR12.3 million a year ago. Between the reporting dates of December 31, 2003, and June 30, 2004, we reduced net debt from EUR105.0 million to EUR99.0 million.

We continue to adhere to our sales revenue and earnings targets for fiscal 2004, and are striving to increase sales revenue in the mid-to upper percentage range of one digit and to double EBIT over the last year’s figures.

At the beginning of the third quarter, the Sartorius Group signed an agreement with a bank consortium to introduce a long-term financing package with a transaction volume totaling EUR140 million. Through this transaction, which consists of a syndicated credit line and an asset-backed securities (ABS) program, a major portion of the currently existing bank liabilities will be refinanced.

Further inquiry note:
Andreas Wiederhold
Treasury & Investor Relations
Tel.: ++49 551 308 1668
andreas.wiederhold@sartorius.com
Tel: +49 (0)551 308 0
FAX: +49 (0)551 308 289
Email: info.investor@sartorius.com

Emittent: Sartorius AG Weender Landstr. 94-108 DE-37075 Göttingen Tel: +49 (0)551 308 0 FAX: +49 (0)551 308 289 Email: info.investor@sartorius.com WWW: http://www.sartorius.com ISIN: DE0007165607, DE0007165631 WKN: 716560, 716563

end of announcement euro adhoc

Indizes: CDAX, Prime All Share, Prime Standard, Technologie All Share
Börsen: official dealing Niedersächsische Börse zu Hannover, Frankfurter Wertpapierbörse; free trade Berliner Wertpapierbörse, Bayerische Börse, Hamburger Wertpapierbörse, Bremer Wertpapierbörse (BWB), Börse Düsseldorf, Baden-Württembergische Wertpapierbörse Branche: Biotechnology
Sprache: Englisch

OTS-ORIGINALTEXT UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS | OTB0006